Related references
Note: Only part of the references are listed.CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
F. Josephson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects
Kyoung-Ah Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects
Kyoung-Ah Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects
Ji-Young Park et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
M Schachter
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2005)
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
KS Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
KT Kivistö et al.
PHARMACOGENETICS (2004)
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
WL Huang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Pharmacokineties of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients
RL Lins et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
YS Lin et al.
MOLECULAR PHARMACOLOGY (2002)
Share Paper
